NCT02264613View on ClinicalTrials.gov

ALRN-6924 in Patients With Advanced Solid Tumors or Lymphomas

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

149

Participants

Timeline

Start Date

October 31, 2014

Primary Completion Date

March 31, 2020

Study Completion Date

April 30, 2020

Conditions
Solid TumorLymphomaPeripheral T-Cell Lymphoma
Interventions
DRUG

ALRN-6924

ALRN-6924 will be administered as an IV infusion

Trial Locations (13)

10065

New York

10461

The Bronx

29605

Greenville

33612

Tampa

34232

Sarasota

35294

Birmingham

37203

Nashville

77030

Houston

80218

Denver

91010

Duarte

98105

Seattle

02114

Boston

02215

Boston

Sponsors
All Listed Sponsors
lead

Aileron Therapeutics, Inc.

INDUSTRY

NCT02264613 - ALRN-6924 in Patients With Advanced Solid Tumors or Lymphomas | Biotech Hunter | Biotech Hunter